Here's Why Charles River Associates Stock Is a Great Pick Right Now
These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Zacks.com Featured Highlights Include NetApp, Cabot, Leidos, Charles River Associates and HCA Healthcare
Evercore Maintains Charles River(CRL.US) With Buy Rating, Maintains Target Price $225
Evercore ISI Sticks to Their Buy Rating for Charles River Labs (CRL)
Express News | Fibrobiologics Inc -on Sept 19, Entered Into a Master Services Agreement With Charles River Laboratories
Is Charles River Laboratories Stock Underperforming the Dow?
Charles River Laboratories International, Inc.'s (NYSE:CRL) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Sword of Justice! The US FTC sues three major pharmaceutical "middlemen", vows to correct the distorted profit chain.
The USA's FTC announced on its official website that it has filed a lawsuit against three major "pharmacy benefit managers" and their affiliated organizations, accusing them of engaging in anti-competitive and unfair kickback practices. FTC also "clearly stated" in the declaration its deep concern about the roles played by eli lilly and co, novo-nordisk a/s, sanofi, and other insulin pharmaceutical companies, and the competition bureau may recommend prosecuting these pharmaceutical companies in future enforcement actions.
Buy Rating for Charles River Associates Backed by Strong A&CE Performance and Positive Growth Indicators
The Analyst Verdict: Charles River In The Eyes Of 10 Experts
Charles River Labs Is Maintained at Neutral by Baird
Charles River Analyst Ratings
Express News | Charles River Laboratories International Inc : Baird Cuts Target Price to $190 From $191
Ori Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving Cell and Gene Therapy Development and Manufacturing
Mizuho Securities Maintains Charles River(CRL.US) With Hold Rating, Announces Target Price $210
Mizuho Securities analyst Ann Hynes maintains $Charles River(CRL.US)$ with a hold rating, and sets the target price at $210.According to TipRanks data, the analyst has a success rate of 63.3% and a
Charles River Comparative Study Reveals That Kytopen's Flowfect Tx Platform Outperforms Conventional Electroporation Platforms
Charles River Laboratories, CEBINA Partner to Accelerate Neurodegenerative Drug Development
Unusual Options Activity: WBD, CRL and Others Attract Market Bets, WBD V/OI Ratio Reaches 73.9
EST Sep 16th Morning Delivery - In the last two hours of trading, 7 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Shareholders in Charles River Laboratories International (NYSE:CRL) Are in the Red If They Invested Three Years Ago